Tackling Solubility Challenges - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Tackling Solubility Challenges
Nanosupensions are among the ways formulation scientists seek to address the problem of solubility.


Pharmaceutical Technology
Volume 36, Issue 3, pp. 40-44

References

1. R.O. Williams, A.B. Watts, and D.A. Miller, "Preface" in Formulating Poorly Water-Soluble Drugs, R.O. Williams, A.B. Watts, and D.A. Miller, Eds. (Springer, 2012), p. v–viii.

2. K.P. O'Donnell and R.O. Williams, "Optimizing the Formulation of Poorly Water- Soluble Drugs," in Formulating Poorly Water-Soluble Drugs, R.O. Williams, A.B. Watts, and D.A. Miller, Eds. (Springer, 2012), pp. 27–28.

3. FDA, Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification (Rockville, MD, Aug. 2000).

4. A.H. Jens-Uwe and R. H. Mueller, Int. J. Nanomedicine 3 (3), 295–310 (2008).

5. H. Chen et al., Drug. Discov. Today 16 (7–8), 354–360 (2011).

6. Alkermes, "NanoCrystal Technology" company information, http://www.alkermes.com/Contract-Services/Technologies/Bioavailability-Enhancement, accessed Feb. 13, 2012.

7. SkyePharma, "2011 Half-Year Results" (London, Aug. 18, 2011).

8. SkyePharma, "Insoluble Drug Delivery Platform" company information, http://www.skyepharma.com/Technology/Oral_Technology/Particle_Engineering_Technologies/Insoluble_Drug_Delivery_Platform/Default.aspx?id=80, accessed Feb. 13, 2012.

9. Aptalis Pharmaceutical Technologies, "Biorise Technology" company information, http://www.aptalispharmaceuticaltechnologies.com/tech_biorise.html, accessed Feb. 13, 2012.

10. B. Trout et al., J. Pharm. Sci. 101 (3), 1178–1188 (2012).

11. P. Van Arnum, Pharm. Technol. 32 (7), 96–98 (2007).

12. P. Van Arnum, Pharm. Technol. 35 (7), 46 (2011).

13. J.Q. Thomassen and P. Holm, presentation at the Nanomedicine and Drug Delivery Symposium (Toronto, Nov. 2008).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
24%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
44%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here